Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.67 |
| ▸ | FAAH | O00519 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.64 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | XBP1 | P17861 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.64 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868075 | 0.98 | MGLL (0.68) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL13078197 | 0.98 | MGLL (0.68) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL14868080 | 0.98 | MGLL (0.68) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL14962677 | 0.98 | MGLL (0.68) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL3482198 | 0.94 | MGLL (0.62) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL406705 | 0.87 | MGLL (0.50) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL14868091 | 0.86 | MGLL (0.52) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL14868093 | 0.86 | MGLL (0.52) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL17170573 | 0.86 | MGLL (0.52) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL3482800 | 0.85 | MGLL (0.54) | MGLLFAAHALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795239-B2 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy | ORASURE TECHNOLOGIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220196641-A1 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | ORASURE TECHNOLIGIES, INC. | 2022-06-23 | — | — | US | disclosed |
| WO-2022133193-A2 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | ORASURE TECHNOLOGIES, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20200239598-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | URSURE, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3250232-B1 | BRANCHED AND LINEAR CHIMERIC COMPOUNDS, POLYNUCLEOTIDES, USES AND METHODS FOR PREPARATION THEREOF | DYNAVAX TECH CORP (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2019075487-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | URSURE, INC. HARVARD LIFE LAB (US) | 2019-04-18 | — | — | WO | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795239-B2 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy | DNTT, POLRMT, SLC29A1 | MGLL 3427/4885FAAH 3206/4885ALDH1A1 227/4885 |
| US-20200239598-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | DNTT, POLRMT, SLC29A1 | MGLL 3427/4885FAAH 3206/4885ALDH1A1 227/4885 |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | MGLL 2653/4885FAAH 3367/4885ALDH1A1 161/4885 |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | MGLL 3983/4885FAAH 2802/4885ALDH1A1 1134/4885 |
| US-20220196641-A1 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | DNTT, SLC29A1, SAMHD1 | MGLL 3824/4885FAAH 3779/4885ALDH1A1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.